Location History:
- Umeå, SE (2002)
- 21 Umea, SE (2004)
- Umea, SE (2007)
Company Filing History:
3 out of 832,966 Years Active: 2002-2007
Title: Anna Arnqvist: Innovator in Blood Group Antigen Research
Introduction
Anna Arnqvist is a prominent inventor based in Umea, Sweden. She has made significant contributions to the field of immunology, particularly in the development of novel blood group antigen binding proteins. With a total of 3 patents, her work has the potential to impact the diagnosis and treatment of gastrointestinal diseases.
Latest Patents
Arnqvist's latest patents include a groundbreaking discovery of a novel blood group antigen binding (BAB) adhesin protein. This protein has been isolated and purified, demonstrating specific binding to fucosylated blood group antigens. The patent discloses the protein sequence of the adhesin, along with the DNA sequences for two genes, babA and babB, which produce highly similar proteins. This adhesin and its corresponding DNA are useful for diagnosis and therapy, particularly in the context of induced infections such as gastritis and acid peptic disease. Additionally, her work introduces a new immunoglobulin composition that exhibits specific activity towards a Lewis antigen binding adhesin, offering innovative methods for treatment and prevention of gastrointestinal diseases.
Career Highlights
Throughout her career, Anna Arnqvist has focused on the intersection of molecular biology and immunology. Her research has led to advancements in understanding how specific proteins can be utilized in medical applications. Her innovative approach has garnered attention in the scientific community, establishing her as a key figure in her field.
Collaborations
Arnqvist has collaborated with notable colleagues, including Thomas Boren and Staffan Normark. These partnerships have enhanced her research efforts and contributed to the successful development of her patented technologies.
Conclusion
Anna Arnqvist's contributions to the field of immunology through her innovative research on blood group antigen binding proteins highlight her role as a leading inventor. Her work not only advances scientific knowledge but also holds promise for improving medical treatments.